Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
2003

Matrix Metalloproteinases in Malignant Mesothelioma

Sample size: 35 publication 10 minutes Evidence: moderate

Author Information

Author(s): Edwards J G, McLaren J, Jones J L, Waller D A, O'Byrne K J

Primary Institution: University Department of Medical Oncology, Leicester Royal Infirmary, UK

Hypothesis

The study investigates the expression of matrix metalloproteinases 2 and 9 in malignant mesothelioma and their correlation with survival.

Conclusion

The study found that active MMP-2 levels are significantly higher in malignant mesothelioma compared to benign pleura, suggesting a role in tumor progression.

Supporting Evidence

  • Active MMP-2 levels were significantly higher in malignant mesothelioma compared to benign pleura.
  • Median survival in the malignant mesothelioma group was 7.5 months.
  • Patients with higher MMP-2 activity had worse survival outcomes.

Takeaway

This study looks at how certain proteins in cancer cells can help us understand how aggressive the cancer is and how long patients might live.

Methodology

The study used gelatin zymography to assess MMP-2 and MMP-9 activity in tumor samples from patients with malignant mesothelioma.

Potential Biases

Potential bias due to the small sample size and the specific patient population studied.

Limitations

The study had a relatively small sample size and may not fully represent the broader population of mesothelioma patients.

Participant Demographics

Patients included 35 with malignant mesothelioma, 12 with inflamed pleura, and 15 with uninflamed pleura.

Statistical Information

P-Value

0.04

Confidence Interval

95% CI 2130–3070

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600920

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication